fbpx

Conservative Portfolio

Amgen Sags on Poor REPETHA Results

Amgen (AMGN) is down as clinical trial data for one of its big drugs wasn’t up to expectations. But AMGN still has multiple blockbusters, and a good pipeline.

McCormick is in a Slower Growth Period

McCormick (MKC) is in a slower growth period right now, but profit growth looks to return to the double-digit level later in the year.

Not a member? Sign up here for $25 a month.